Vnitr Lek 2014, 60(4):310-315

Treatment of heart failure in diabetic patients

Jaromír Hradec
III. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA

Heart failure occurs in diabetic patients and vice versa, among patients with heart failure is high prevalence of diabetes mellitus. Treatment of heart failure in diabetics is not substantially different from the treatment of heart failure in non-diabetic patients. It is based on ACE-inhibitors, beta-blockers and mineralocorticoid receptor blockers. In advanced heart failure the treatment with various devices reaches importance, for example biventricular pacing for cardiac resynchronization. Recently, it has been discussed the question of long-term cardiovascular safety of hypoglycaemic drugs. Older anti-diabetic agents such as insulin, metformin, and sulfonylurea are considered to be cardiovascular safe. However, rosiglitazone from thiazolidinedione class increases incidence of cardiovascular events, resulting in cancellation of its registration in Europe and its considerably limited use in the United States. Therefore, cardiovascular safety is tested very carefully in clinical trials in new anti-diabetic agents that affect incretin system. Recently, saxagliptin has shown to increase incidence of heart failure in diabetic patients.

Keywords: cardiovascular risk; diabetes mellitus; heart failure; peroral antidiabetics

Received: January 20, 2014; Published: April 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hradec J. Treatment of heart failure in diabetic patients. Vnitr Lek. 2014;60(4):310-315.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McMurray JV, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33(14): 1787-1847. Go to original source... Go to PubMed...
    2. Rydén L, Grant P, Anker SD et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34(39): 3035-3087. Go to original source... Go to PubMed...
    3. Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376 (9744): 875-885. Go to original source... Go to PubMed...
    4. Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102(1): 11-22. Go to original source... Go to PubMed...
    5. Gitt AK, Halle M, Hanefeld M et al. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without? Eur J Heart Fail 2012; 14(12): 1389-1400. Go to original source... Go to PubMed...
    6. Masoudi FA, Inzucchi SE, Wang Y et al. Thiazolidinediones, metformin and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005; 111(5): 583-590. Go to original source... Go to PubMed...
    7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356(24): 2457-2471. Go to original source... Go to PubMed...
    8. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007; 356(24): 2522-2524. Go to original source... Go to PubMed...
    9. Petrie JR. The cardiovascular safety of incretin-based therapies: a review of the evidence. Cardiovasc Diabetol 2013; 12: 130. Dostupné z DOI: <http://doi:10.1186/1475-2840-12-130>. Go to original source... Go to PubMed...
    10. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl. J Med 2013; 369(14): 1317-1326. Go to original source... Go to PubMed...
    11. White WB, Cannon ChP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369(14): 1327-1335. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.